Inimmune’s focus is to discover and develop disease-modifying immunotherapies. Currently, our pipeline includes two clinical-stage Toll-like receptor (TLR) agonists in immuno-oncology and allergy. Both of these TLR agonists generated disease-modifying therapeutic responses in pre-clinical models. Late-stage pre-clinical programs are focused on developing innate immune agonists as next-generation vaccine adjuvants and discovery-stage projects are centered around novel, non-TLR innate immune agonists and antagonists.
Inimmune’s focus is to discover and develop disease-modifying immunotherapies. Currently, our pipeline includes two clinical-stage Toll-like receptor (TLR) agonists in immuno-oncology and allergy. Both of these TLR agonists generated disease-modifying therapeutic responses in pre-clinical models. Late-stage pre-clinical programs are focused on developing innate immune agonists as next-generation vaccine adjuvants and discovery-stage projects are centered around novel, non-TLR innate immune agonists and antagonists.
Inimmune has completed a Phase I clinical trial evaluating the safety and tolerability of INI-2004 (a TLR4 agonist) as a treatment for allergic rhinitis. Inimmune also has an ongoing Phase I clinical trial evaluating the safety and tolerability of INI-4001 (a TLR7/8 agonist) as a cancer treatment, both alone and in combination with existing checkpoint inhibitors.
Inimmune is a clinical-stage, fast-moving innovative biotech company focused on the discovery and development of novel immunotherapeutics for cancer, allergy, autoimmunity, and vaccines. Inimmune has a deep pipeline consisting of two clinical-stage assets and early and late pre-clinical assets, all poised to change the landscape of immunotherapy and vaccine adjuvants.
We partner with some of the best universities and biotech companies. Want to co-create and develop novel immunotherapeutics to improve human health?
We are a biotech company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. We have extensive expertise in synthetic and process chemistry, drug formulation, immunology, and clinical translation. Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. Equal opportunity applies to all aspects of our employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits.
